Fiocruz and Anlis link up for yellow fever vaccine production in Argentina

Brazil’s scientific institution for R&D, Fiocruz, through the Immunobiological Technology Institute (Bio-Manguinhos/Fiocruz) have signed a term of commitment with the National Administration of Laboratories and Institutes of Health Dr Carlos Malbrán (Anlis), aimed at enabling the Argentine institution to produce and supply the yellow fever vaccine in its country.

The signing took place after the meeting of Mercosur health ministers at Itamaraty, in Brasília, and was attended by the ministers of health of Brazil, Nísia Trindade Lima, and Argentina, Carla Vizzotti; the director of Bio-Manguinhos, Maurício Zuma; and the director of Anlis, Pascual Fidelio.

Currently, Bio-Manguinhos/Fiocruz is one of the four global producers of the yellow fever vaccine pre-qualified by the World Health Organization (WHO). Thus, in addition to meeting the national demand of the Unified Health System (SUS), Fiocruz plays a key role in supplying these vaccines to countries in Latin America, the Caribbean and Africa, through United Nations agencies.